Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G. Soergel, Lynn R. Webster, Franck Skobieranda et al.|Pain|2014Cited by 264
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute painEugene R. Viscusi, Franck Skobieranda, Lynn R. Webster et al.|Pain|2015Cited by 209
(433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (μ-GPS), vs. Morphine: an analysis of two phase 2 randomized clinical trialsEugene R. Viscusi, Franck Skobieranda, Ruth Ann Subach et al.|Journal of Pain|2016Cited by 2